Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, April 23, 2025

View Back issues

EpiPen antitrust

KANSAS CITY, Kan. — A federal judge allowed a class of EpiPen users to pursue antitrust claims against drugmaker Mylan, ruling they sufficiently showed the company, in cooperation with Pfizer, attempted to dominate the emergency allergy medication market and delay entry of a generic version.

Click here to read the ruling.

Categories / Briefs, Business, Health

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

Loading...